Ryanair Gains on Narrower Net Loss; Regeneron Melanoma Trial Failure | Stock Movers

Market Intelligence Analysis

AI-Powered 60% FREE-ANALYSIS-RULE-BASED-ANALYSIS
Why This Matters

Analysis of stock market developments showing bearish sentiment.

Sentiment
Bearish
AI Confidence
60%
Time Horizon
Short Term
Affected Symbols

Article Context

Note: This is a brief excerpt for context. Click below to read the full article on the original source.

On this episode of Stock Movers with Alexis Christoforous: - NextEra Energy (NEE) agreed to pay about $67 billion in stock for Dominion Energy (D) in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. The deal would give NextEra a swathe of electricity assets stretching across Virginia and the Carolinas. - Ryanair (RYAAY) gains as it delivered a decent end to the year, but flagged impact ahead from rising costs. The airline said unit costs for 2027 could increase by a mid-single digit percentage, with concerns over current unhedged jet fuel prices, and also impact from higher crew and aircraft maintenance costs. - Regeneron Pharmaceuticals (REGN) shares drop after the drugmaker’s phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi downgraded its rating on the stock following the “disappointing” trial update. (Source: Bloomberg)

Continue Reading
Full article on Bloomberg
Read Full Article
AI Breakdown

Summary

Analysis of stock market developments showing bearish sentiment.

Time Horizon

Short Term

Original article published by Bloomberg on May 18, 2026.
Analysis and insights provided by AnalystMarkets AI.